IPFA/EBA WORKSHOP ON

Plasma Collection



AMSTERDAM



14 – 15 January 2020

Corendon Village Hotel Amsterdam
the Netherlands

eba
European Blood Alliance

IPFA
international plasma and fractionation association

Objective of the meeting

To promote increased plasma collection from voluntary non-remunerated donors and to identify the barriers and potential solutions to achieving this objective.

www.ipfa.nl **www.europeanbloodalliance.eu**

Programme

Day 1: Tuesday 14 January 2020

09.00 hrs
Session 1: Welcome
Session chair: Paul Strengers

- Welcome and introduction:
    - Why is European plasma strategic independence important?
        - International Plasma and Fractionation Association
          Paul Strengers, the Netherlands
        - European Blood Alliance
          Pierre Tiberghien, France
- European Commission views
  Stefaan van der Spiegel, DG Health & Food Safety (SANTE), Belgium
- Recommendations from the EDQM 2019 Symposium on Plasma Supply Management
  Guy Rautmann, European Directorate for the Quality of Medicine and Healthcare, France
- Plasma Derived Medicinal Products (PDMPs) and plasma supply into the future
  Patrick Robert, The Marketing Research Bureau, Inc., USA

10.15 hrs
Coffee Break

10.45 hrs
Session 2: Responding to increased demand for Plasma Derived Medicinal Products
Session chair: Cees Smit

The global demand for plasma for fractionation is expected to increase for the foreseeable future driven primarily by the increasing clinical use of immunoglobulin products. In this session colleagues from Belgium, Australia and Canada will describe how their strategies and policies have evolved to ensure a safe and secure national supply of plasma (both recovered and source) and PDMPs to meet patient needs – including monitoring and management of clinical use.

- Belgian experience - *Philippe Vandekerckhove, Belgian Red Cross Flanders Blood Service, Belgium*
- Australian experience – *Sue Wilkes, Australian Red Cross Lifeblood, Australia*
- Navigating complexity: Ensuring security of supply of PDMPs in the Canadian context - *Graham Sher, Canadian Blood Services, Canada*
- Panel discussion



12.15 hrs
LUNCH BREAK

Lunch at Village All Inclusive Restaurant
Kindly sponsored by: Fresenius Kabi

FRESENIUS KABI
caring for life

13.45 hrs
SESSION 3: DONOR RECRUITMENT

Session chair: Christian Erikstrup

Without blood and plasma donors, there would be no blood products to transfuse and no plasma donations for pharmaceutical drug production. However, often as little as 2%–3% of the population is registered as blood donor and donor numbers have been decreasing over the years. At the same time, the demand for specific blood products, especially plasma-derived ones, is increasing in times of demographic change, immigration and longevity. Hence, it is crucial that a country's donor pool is sufficient, healthy and diverse enough to ensure access to every blood type and blood product that is needed. Targeted recruitment and retention of donors with specific characteristics are key in meeting the demands and improve donor management. The aim of this session is to present evidence on donor motivation and barriers, show best practices from different countries in recruiting and retaining plasma donors and discuss ethical aspects around donor selection and blood safety.

- Recruitment strategies and incentives for plasma donors - *Barbara Masser, University of Queensland, Australia*
- Ethics and safety in donor selection – *Koen Kramer, Utrecht University, the Netherlands*
- Who gives (plasma)? Motivators and barriers - *Eva-Maria Merz, Sanquin, the Netherlands*
- Plasma donor recruitment and retention/donor health: role of donor associations – *Alice Simonetti, FIODS, Italy*
- Panel discussion

15.30 hrs
COFFEE BREAK

NOTES

Programme

16.00 hrs
Session 4: Donation process
Session chair: Anne-Marie van Walraven

The efficiency of the donation process to collect plasma, both source and recovered, is dependent on various factors. These factors are e.g. related to management elements, donor characteristics and technical aspects. During this session you will learn how to optimise the management of the collection process, personnel and the efficiency of the donation and processing of blood and plasma.

- Management of blood and plasma collection - *Frederic Bigey, Établissement Français du Sang, France*
- Improving apheresis efficiency - *Hans Vrielink, Sanquin Blood Foundation, the Netherlands*
- Efficiency of collection practices. Case studies - *Stephan Walsemann, Scinomed Deutschland GmbH (formerly of European Plasma Alliance and Bavarian Red Cross), Germany*
- Personnel requirements in European plasma centers – revisited - *Matthias Gessner, European Plasma Alliance, Austria*

17.30 hrs
End of Day 1

18.30 hrs
Departure for dinner at the Kompaszaal





Day 2: Wednesday 15 January 2020

09.30 hrs
Session 5: Manufacturers' Session

Session chair: Françoise Rossi

This session will provide opportunity for industries providing equipment, materials and support to blood centres and establishments to present on technical and scientific developments in their companies in support of the goal of increased plasma supply.

- ***Scinomed Ltd***
  Scinomed's New Plasmapheresis Platform. "Does it Deliver...?" - *Stephan Walsemann*

10.00 hrs
Coffee Break

10.30 hrs
Session 6: Donor health

Session chair: Rut Norda

Plasma donors often donate frequently. With the scale-up of plasma donation it is of paramount importance to assure that the procedure is safe. In this session we will present the knowledge on short and long term effects of plasmapheresis. We will also discuss what knowledge is missing and what studies we need to perform.

- Impact on short term donor health – *Johanna Castrén, Finnish Red Cross Blood Service, Finland*
- Impact on long term donor health – *Jingcheng Zhao, Karolinska Institute, Sweden*
- A plea for European donor vigilance – *Christian Erikstrup, Aarhus University Hospital, Denmark*
- Panel discussion

12.00 hrs
Lunch Break

Lunch at Village All Inclusive Restaurant
Kindly sponsored by: Grifols Diagnostic Solutions

GRIFOLS

Programme

13.30 hrs
Session 7: Quality considerations for plasma for fractionation

Session chair: Johanna Castrén

The collection and preparation of blood components and plasma for fractionation are highly regulated activities requiring comprehensive quality management systems to meet the standards prescribed by regulatory authorities and the plasma fractionation industry. This session will consider specific quality requirements for plasma intended for fractionation from the perspectives of both regulators and manufacturers together with a discussion of the wider benefits of plasma quality programmes for blood establishments.

- Benefits of plasma quality programmes in blood establishments – *Françoise Rossi, International Plasma and Fractionation Association, the Netherlands*
- GMP/GP specific requirements for plasma for fractionation – *Sébastien Merrien, Laboratoire français du Fractionnement et des Biotechnologies, France*
- Regulatory considerations for plasma for fractionation – *Jens Reinhardt, Paul-Ehrlich-Institut, Germany*
- Panel discussion

15.00 hrs
Session 8: Facilities and logistics – international experiences

Session chair: Frederic Bigey

This session will share the experiences from European, Australian and Canadian Blood establishments of their current development and future plans for the efficient and cost effective large scale collection of recovered and source plasma from VNRDs. The aim of the session will be to identify key considerations for the development of infrastructure and logistical arrangements to optimize capacity, efficiency, cost effectiveness and donor experience.

- Italy - *Giancarlo Liumbruno, Italian National Blood Center (Rome), Italy*
- Germany - *Franz Weinauer, Blood Transfusion Service BSD/BRK, Germany*
- Australia – *Sue Wilkes, Australian Red Cross Lifeblood, Australia*
- The ongoing plan to increase the collection of plasma for fractionation at Héma-Québec: successes and lessons learned – *Marc Germain, Héma-Québec, Canada*
- Panel discussion

16.45 hrs
Concluding remarks

- A roadmap / framework to increase plasma collection by blood establishments
- General summary

17.00 hrs
Farewell drinks



NOTES

Programme

Notes

This Workshop is kindly sponsored by:

Fresenius Kabi | Grifols Diagnostic Solutions | Haemonetics Corporation | Roche Molecular Diagnostics | Scinomed Ltd